trending Market Intelligence /marketintelligence/en/news-insights/trending/4v1VX3sWXt2XUZkkV0Jf_g2 content esgSubNav
In This List

Astellas, Ironwood constipation drug meets endpoint in phase 3 trial in Japan

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Astellas, Ironwood constipation drug meets endpoint in phase 3 trial in Japan

Astellas Pharma Inc. and Ironwood Pharmaceuticals Inc. reported that the phase 3 trial of linaclotide for chronic constipation, conducted in Japan, met its primary endpoint.

Linaclotide-treated patients showed statistically significant improvement in mean spontaneous bowel movement frequency compared to placebo-treated patients. The companies will use efficacy and safety data to pursue regulatory approval for the additional indication in Japan.

The drug is approved in Japan as prescription treatment for adults with irritable bowel syndrome with constipation. In the U.S., linaclotide is approved, and sold under the brand name Linzess, for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.